Pharma BD Deal Intelligence
On August 3, 2026, Curium U.S. Holdings LLC and Lantheus Holdings, Inc. announced a definitive merger agreement under which Lantheus will merge with a wholly owned subsidiary of Curium U.S. Lantheus shareholders receive $102.50 per share in cash at closing plus non-transferable contingent value rights worth up to $12.00 per share, for total consideration of up to $114.50 per share and an aggregate transaction value of up to approximately $8.0 billion. The cash consideration represents a 38% premium to Lantheus' unaffected 60-day VWAP and a 29% premium to its unaffected 30-day VWAP. The CVR milestones are tied to sales of the Global Neurology Diagnostics portfolio (>$300 million and >$350 million) and the Global DEFINITY business (>$400 million), measured through the fiscal year ending December 31, 2030. Lantheus' board unanimously approved the transaction, which is expected to close in the first half of 2027 subject to shareholder and regulatory approvals. NOTE: ingested at pending_review by bd-enrichment 2026-08-05.
← Browse all deals · How we score deals
More: 2026 deals